Most Read Articles
02 Jul 2020
The risk for subdeltoid bursitis increases following influenza vaccination, but the absolute risk appears to be small, according to a recent study.

Product Highlight - RENVELA

24 Jul 2020

Product Characteristics:

  •  For phosphorus control in patients with Chronic Kidney Disease on dialysis.1
  •  The first non-calcium based phosphate binder the lowers progression of vascular calcification vs calcium based phosphate binder.2
  •  Renvela Powder indicated for the control of serum phosphorus in pediatric patients more than 6 years of age.3
  •  Sevelamer carbonate (Renvela) - SRP Php 56.4

References:
(1) Renvela Tablet Product Insert CCDS Version 4 Date of leaflet revision: September 2015
(2) Block GA, Raggi P, Bellasi A, Koolenga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kindey Int. 2007;71:438-441.
(3) St. Peter WL, Liu J Weinhandi E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomize trial using claims data. Am J, Kidney Dus. 2008-51;445-454.
(4) Mercury Drugstore Price, updated June 2020.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Philippines digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Jul 2020
The risk for subdeltoid bursitis increases following influenza vaccination, but the absolute risk appears to be small, according to a recent study.